What is the risk of getting a second cancer after CLL treatment
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Risk of Second Cancer After CLL Treatment
This is an important question, and I appreciate you asking it. Let me explain what we know about this risk based on current medical evidence.
What the Research Shows
The risk of developing a second cancer (called a "secondary malignancy") after CLL treatment exists, but the actual risk varies significantly depending on several factors:
Key Factors That Affect Your Risk:
1. Type of Treatment You Received
- Different CLL treatments carry different risks
- Chemotherapy-based treatments (like fludarabine or cyclophosphamide) have been associated with secondary malignancies in some patients
- Newer targeted therapies (BTK inhibitors like ibrutinib, or BCL2 inhibitors like venetoclax) have lower reported rates of secondary cancers
2. Length of Time Since Treatment
- Second cancers typically develop years after initial treatment
- Your risk may change over time depending on what therapy you received
3. Your Individual Factors
- Age at diagnosis
- Overall health and immune function
- Genetic predispositions
- Lifestyle factors (smoking, sun exposure, etc.)
What We Know About Specific Treatments
According to NCCN Guidelines for CLL, when discussing treatment options like CAR T-cell therapy (lisocabtagene maraleucel), the safety data showed that second primary malignancies were reported in 9% of patients in clinical trials, but none were related to the CAR T-cell treatment itself.
This suggests that while second cancers can occur in CLL patients, they may not always be directly caused by the cancer treatment.
Important Context
The good news is that:
- Modern CLL treatments are increasingly effective with better safety profiles
- Many newer therapies (targeted drugs) appear to have lower secondary cancer risks than older chemotherapy approaches
- Regular monitoring and preventive health measures can help catch any new cancers early
Questions to Ask Your Oncologist
Since your specific risk depends on YOUR individual situation and treatment plan, ask your care team:
-
"Based on the specific treatment you're recommending for me, what is my estimated risk of developing a second cancer?"
-
"Are there screening tests or preventive measures I should follow to monitor for secondary cancers?"
-
"How does my age, health status, and other factors affect my personal risk?"
-
"What lifestyle changes can I make to reduce my overall cancer risk?"
-
"How often should I have follow-up visits to monitor for new cancers?"
What You Can Do
While you can't eliminate the risk entirely, you can:
- Maintain regular follow-up appointments with your oncology team
- Avoid known cancer risk factors (smoking, excessive sun exposure)
- Stay up-to-date with cancer screening recommendations for your age
- Report any new symptoms to your doctor promptly
- Maintain a healthy lifestyle with good nutrition and exercise
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Source Guidelines
NCCN Guidelines for Patients: Chronic Lymphocytic Leukemia (2026)Browse all NCCN Guidelines for Patients →Related Services
Services that may help with treatment for CLL patients
Have your records handy? Upload them for a deeper, personalized analysis →